The European healthcare technology IPO market is entering a phase of “rational exuberance” in 2026 after a dry spell from late 2021 through 2025, with the window reopening but remaining highly selective. In early 2026, four biotech IPOs raised over $1 Billion in the busiest seven-day stretch in about a year, including Agomab Therapeutics’ $200 million NASDAQ listing, Eikon Therapeutics’ $381 million deal, Veradermics’ $256 million NYSE debut, and SpyGlass Pharma’s $150 million NASDAQ float. Market observers expect 30-35 biotech IPOs globally in 2026 compared with just 11 in 2025, but capital is concentrating on product-focused companies with clinical data, and premium valuations in 2026-2027 will be reserved for businesses with 60-80% gross margins, clear profitability paths, and Artificial Intelligence driven efficiency.
European companies face structural constraints, with exits still lagging the United States despite reforms at Deutsche Boerse, Euronext, and in the United Kingdom. The “Delaware flip” dominates among high-growth European healthtech companies, which increasingly re-domicile to access NASDAQ liquidity and valuation parity with United States peers, even as European exchanges cut fees, relax listing rules, and standardise prospectuses. Key 2026 Tier 1 candidates include CMR Surgical in the United Kingdom with a $3–4B valuation and a dual-track process weighing an LSE or NASDAQ IPO against a potential $4B sale, Huma in the United Kingdom with over $300M raised and LSE ambitions, Oura Health in Finland eyeing a public option with expected $1 billion in revenue in 2025 and a reported $11 billion valuation target after a $900 million Series E, and Kry in Sweden as a strong digital health IPO contender. Tier 2 names for late 2026-2027 include Doctolib in France with a $6.4B valuation, Neko Health in Sweden at $1.8B and expanding to New York in spring 2026, Sword Health in Portugal and the United States with a $4B valuation, Flo Health in the United Kingdom with a $1B+ valuation, Owkin in France with a $1B+ valuation, Isomorphic Labs in the United Kingdom with $600M raised, Corti in Denmark after a $60M Series B, and Distalmotion in Switzerland after a $150M Series G.
Public market benchmarks have shifted sharply upward, with medtech issuers expected to show $40M-$60M+ minimum annual run-rate revenue and 65%-80% target gross margins, while healthtech and digital health peers are expected to show $200M+ minimum annual run-rate revenue, 60%-80% target gross margins, 20%-25% growth, and a clear path to non-GAAP operating income or free cash flow positive. Regulatory forces further shape the field: the EU Artificial Intelligence Act, fully enforced from March 2026, classifies many medical Artificial Intelligence tools as “high-risk” and makes opaque models effectively un-investable, while EU MDR and IVDR impose costly compliance that turns regulatory approvals into “compliance moats.” The European Health Data Space is positioned as “the single most significant structural driver for HealthTech investment in 2026” by mandating secondary use of electronic health data and creating a new curated data asset class that benefits platforms like Owkin and Huma. Looking to 2027, the pipeline features Sword Health with a $240 million revenue run rate and a guided 2028 IPO that could accelerate, a possible Doctolib listing on Euronext or NASDAQ once profitable, a Neko Health IPO after United States traction, a Flo Health debut building on $1B+ valuation and menopause and B2B expansion, and a potential NASDAQ listing for Isomorphic Labs if its Artificial Intelligence drug discovery pipeline matures. Rising exit pressure from $180-400 billion in annual incumbent revenue losing exclusivity, a closing valuation gap with the United States, the GLP-1 ecosystem, and mounting secondary market volumes above $210 billion all point to a more active but more discriminating market, even as risks from an Artificial Intelligence valuation bubble, geopolitical volatility, European liquidity gaps, and regulatory burden continue to threaten sentiment.
